PARA-BKRS 1.0%W/V PARENTERAL ORDINARY INFUSION VIALS/BOTTLES Uganda - angličtina - National Drug Authority

para-bkrs 1.0%w/v parenteral ordinary infusion vials/bottles

bkrs pharma pvt. ltd. - paracetamol - parenteral ordinary infusion vials/bottles - 1.0%w/v

FLUCO-BKRS 0.2% W/V PARENTERAL ORDINARY INFUSION VIALS/BOTTLES Uganda - angličtina - National Drug Authority

fluco-bkrs 0.2% w/v parenteral ordinary infusion vials/bottles

bkrs pharma pvt. ltd. - fluconazole - parenteral ordinary infusion vials/bottles - 0.2% w/v

OFLO-BKRS 0.2% W/V PARENTERAL ORDINARY INFUSION VIALS/BOTTLES Uganda - angličtina - National Drug Authority

oflo-bkrs 0.2% w/v parenteral ordinary infusion vials/bottles

bkrs pharma pvt. ltd. - ofloxacin - parenteral ordinary infusion vials/bottles - 0.2% w/v

LEXAR 500MG PARENTERAL ORDINARY INFUSION VIALS/BOTTLES Uganda - angličtina - National Drug Authority

lexar 500mg parenteral ordinary infusion vials/bottles

bkrs pharma pvt. ltd. - levofloxacin hemihydrate - parenteral ordinary infusion vials/bottles - 500mg

BKSR Modular Tibial Tray Neutral - Uncoated knee tibia prosthesis, metallic Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

bksr modular tibial tray neutral - uncoated knee tibia prosthesis, metallic

ortho development pty ltd -

RABEPRAZOLE SODIUM- rabeprazole tablet, delayed release Spojené státy - angličtina - NLM (National Library of Medicine)

rabeprazole sodium- rabeprazole tablet, delayed release

preferred pharmaceuticals inc. - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - rabeprazole sodium 20 mg - rabeprazole sodium delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (gerd). for those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium may be considered. rabeprazole sodium delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (gerd maintenance). controlled studies do not extend beyond 12 months. rabeprazole sodium delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks. rabeprazole sodium delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. most patients heal within four weeks. rabeprazole sodium delayed-release t

Fluoxetine 20mg capsules Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

fluoxetine 20mg capsules

strides pharma uk ltd - fluoxetine hydrochloride - oral capsule - 20mg

Ciprofloxacin 250mg tablets Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

ciprofloxacin 250mg tablets

torrent pharma (uk) ltd - ciprofloxacin hydrochloride - oral tablet - 250mg

Ciprofloxacin 500mg tablets Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

ciprofloxacin 500mg tablets

torrent pharma (uk) ltd - ciprofloxacin hydrochloride - oral tablet - 500mg

Ciprofloxacin 500mg tablets Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

ciprofloxacin 500mg tablets

kent pharma (uk) ltd - ciprofloxacin hydrochloride - oral tablet - 500mg